Featured Posts

To top
11 Sep

Angela Caglia Debuts Recent Serum, Martin Brok Invests in

Celebrity aesthetician Angela Caglia is debuting her recent serum exclusively at Violet Grey, concurrently revealing her brand has received funding from former Sephora chief executive officer Martin Brok.

Cell Forté Serum, which might be launched Oct. 2 and priced at $395, is the results of an eight-year collaboration with stem cell scientist Donna Chang, CEO of Hope Bioscience, to search out stem cell technology without the controversy of embryonic stem cells or the ineffectiveness of plant stem cells, in line with Caglia, whose clients include Barbra Streisand, Helena Christensen, Camila Morrone, Riley Keough and Sting. 

“All of us start off as a ball of stem cells,” she explained. “And of all those cells, the mesenchymal stem cell is the superhero — it’s the one which becomes our hair, heart, bones and skin. Once we are young, it regenerates our cells so wounds heal faster. As we become old, these stem cells decline. That’s where we are available in. We found a technique to harness ethically sourced patented protein-rich human stem cell conditioned media. It has no human DNA, but all of the potent secretions of natural growth aspects, exosomes, cytokines and proteins to brighten and reduce effective lines and wrinkles without disrupting the barrier.” 

Violet Grey, now owned by Farfetch, could have the exclusive for six months.

“When Angela unveiled the key serum she’d been toiling away on for years during one in every of her transformational facials last winter, it took me about three seconds to press her (hard!) for the exclusive,” said Sarah Brown, executive director at Violet Grey. 

Sales of the serum are projected to achieve $5 million over the subsequent 12 months, in line with the brand, which is developing other stock keeping units within the range.

As for the investment from Brok, the previous CEO of Sephora who’s now on the board of Revlon, Caglia told WWD that they were introduced by a mutual acquaintance.

“What I like about Martin is that he has such a high-level perspective on what the patron wants and the way the patron desires to know the journey and the story,” said Caglia. “He’s also our adviser. I actually have monthly calls with him and we go over things and he has just really been supportive and he’s helped me quite a bit when it comes to positioning the product in the massive picture.”

Terms weren’t disclosed, although Caglia said he invested earlier this 12 months and has since doubled that investment.

“During my skilled profession, I actually have had the privilege of working alongside a number of the world’s most revolutionary beauty brands as they launched to market,” said Brok in a press release. “I feel that Angela Caglia, along with her passion for stem cell technology, has created a novel product that’s within the vanguard of medical science bringing the most recent scientific knowledge to the sweetness industry.”

The newest investment comes after the skincare brand closed its first funding round in March. Terms of that deal were also not shared, aside from that the round was led by a non-public individual.

Recommended Products

No Comments

Sorry, the comment form is closed at this time.